Kronos Bio to Present p300 KAT Inhibition Data at ACR Convergence 2024

Kronos Bio, Inc. (Nasdaq: KRON), a company focused on developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, has announced that it will present preclinical data from its p300 KAT inhibitor program for autoimmune indications. This presentation is scheduled to take place at the American College of Rheumatology's annual meeting, ACR Convergence 2024, which will be held from November 14 to 19, 2024, in Washington, DC.

Kronos Bio is investigating the potential of a p300 KAT inhibitor for autoimmune diseases due to the involvement of interferon regulatory factor 4 (IRF4) and p300 in B cells, T cells, and other immune cells. The forthcoming data presentation will underscore the role of p300 in inflammation, highlighting the company's progress towards announcing a development candidate for autoimmune diseases by the end of 2024.

Peter Rahl, Ph.D., Vice President of Discovery Biology at Kronos Bio and corresponding author of the abstract, expressed optimism about the initial data. He stated, "We are leveraging our proprietary discovery engine that decodes complex transcription factor regulatory networks to develop a p300 KAT inhibitor to potentially treat autoimmune diseases. We are highly encouraged by these initial data demonstrating that p300 KAT inhibition can modulate the activity and function of multiple pro-inflammatory signaling pathways in chronic inflammatory diseases at well-tolerated in vivo exposures." Rahl emphasized that the multifaceted nature of autoimmune diseases suggests that an orally available therapeutic that selectively inhibits pro-inflammatory transcription in multiple cell types could address a fundamental cause of inflammation.

The details for the ACR Convergence 2024 abstract are as follows:
- Title: p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines
- Presenter: Peter Rahl, Ph.D., Vice President, Discovery Biology
- Abstract Number: 2598
- Poster Session: Cytokines & Cell Trafficking
- Date and Time: Monday, November 18, 2024, from 4:15 p.m. to 4:30 p.m. EST

The presentation will be accessible under the Science & Pipeline section of the Kronos Bio website starting November 14, 2024. The abstract is also available on the American College of Rheumatology’s website.

Kronos Bio, Inc. is a clinical-stage company dedicated to developing small molecule therapeutics that address deregulated transcription, a key factor in cancer and other diseases. The company's proprietary discovery engine decodes complex transcription factor regulatory networks to identify druggable cofactors. Kronos Bio focuses on screening and optimizing small molecules that target these cofactors in a tumor-specific context, leading to a robust preclinical pipeline and two internally developed drug candidates. KB-0742 targets CDK9, aiming to address MYC deregulation in solid tumors, while KB-9558 targets p300 to address IRF4 dependence in multiple myeloma.

Kronos Bio is headquartered in San Mateo, California, with a research facility in Cambridge, Massachusetts.